1
|
Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnölzer M, Lasitschka F, Lasischka F, Neuhuber WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V, Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornalley PJ, Edelstein D, Nau C, Forbes J, Humpert PM, Schwaninger M, Ziegler D, Stern DM, Cooper ME, Haberkorn U, Brownlee M, Reeh PW, Nawroth PP. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012; 18:926-33. [PMID: 22581285 DOI: 10.1038/nm.2750] [Citation(s) in RCA: 359] [Impact Index Per Article: 29.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2011] [Accepted: 03/22/2012] [Indexed: 12/13/2022]
Abstract
This study establishes a mechanism for metabolic hyperalgesia based on the glycolytic metabolite methylglyoxal. We found that concentrations of plasma methylglyoxal above 600 nM discriminate between diabetes-affected individuals with pain and those without pain. Methylglyoxal depolarizes sensory neurons and induces post-translational modifications of the voltage-gated sodium channel Na(v)1.8, which are associated with increased electrical excitability and facilitated firing of nociceptive neurons, whereas it promotes the slow inactivation of Na(v)1.7. In mice, treatment with methylglyoxal reduces nerve conduction velocity, facilitates neurosecretion of calcitonin gene-related peptide, increases cyclooxygenase-2 (COX-2) expression and evokes thermal and mechanical hyperalgesia. This hyperalgesia is reflected by increased blood flow in brain regions that are involved in pain processing. We also found similar changes in streptozotocin-induced and genetic mouse models of diabetes but not in Na(v)1.8 knockout (Scn10(-/-)) mice. Several strategies that include a methylglyoxal scavenger are effective in reducing methylglyoxal- and diabetes-induced hyperalgesia. This previously undescribed concept of metabolically driven hyperalgesia provides a new basis for the design of therapeutic interventions for painful diabetic neuropathy.
Collapse
Affiliation(s)
- Angelika Bierhaus
- Department of Medicine I and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Schweitzer K, Mueller J, Dehmer T, Krüger R, Gasser T, Berg D. Prädisposition für eine vermehrte Echogenität der Substantia nigra. Akt Neurol 2005. [DOI: 10.1055/s-2005-919201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
3
|
Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AAR, Andrassy M, Schiekofer S, Schneider JG, Schulz JB, Heuss D, Neundörfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Haering HU, Schleicher E, Kasper M, Stern DM, Arnold B, Nawroth PP. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2005; 114:1741-51. [PMID: 15599399 PMCID: PMC535062 DOI: 10.1172/jci18058] [Citation(s) in RCA: 204] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2003] [Accepted: 10/07/2004] [Indexed: 11/17/2022] Open
Abstract
Molecular events that result in loss of pain perception are poorly understood in diabetic neuropathy. Our results show that the receptor for advanced glycation end products (RAGE), a receptor associated with sustained NF-kappaB activation in the diabetic microenvironment, has a central role in sensory neuronal dysfunction. In sural nerve biopsies, ligands of RAGE, the receptor itself, activated NF-kappaBp65, and IL-6 colocalized in the microvasculature of patients with diabetic neuropathy. Activation of NF-kappaB and NF-kappaB-dependent gene expression was upregulated in peripheral nerves of diabetic mice, induced by advanced glycation end products, and prevented by RAGE blockade. NF-kappaB activation was blunted in RAGE-null (RAGE(-/-)) mice compared with robust enhancement in strain-matched controls, even 6 months after diabetes induction. Loss of pain perception, indicative of long-standing diabetic neuropathy, was reversed in WT mice treated with soluble RAGE. Most importantly, loss of pain perception was largely prevented in RAGE(-/-) mice, although they were not protected from diabetes-induced loss of PGP9.5-positive plantar nerve fibers. These data demonstrate, for the first time to our knowledge, that the RAGE-NF-kappaB axis operates in diabetic neuropathy, by mediating functional sensory deficits, and that its inhibition may provide new therapeutic approaches.
Collapse
Affiliation(s)
- Angelika Bierhaus
- University of Heidelberg, Department of Medicine I, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004; 88:494-501. [PMID: 14690537 DOI: 10.1046/j.1471-4159.2003.02210.x] [Citation(s) in RCA: 287] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Inflammation has been implicated in the pathogenesis of Parkinson's disease (PD). In the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD, inducible NO synthase (iNOS) derived nitric oxide (NO) is an important mediator of dopaminergic cell death. Ligands of the peroxisome proliferator-activated receptor (PPAR) exert anti-inflammatory effects. We here investigated whether pioglitazone, a PPARgamma agonist, protected mice from MPTP-induced dopaminergic cell loss, glial activation, and loss of catecholamines in the striatum. As shown by western blot, PPARgamma was expressed in the striatum and the substantia nigra of vehicle- and MPTP-treated mice. Oral administration of 20 mg/(kg day) of pioglitazone protected tyrosine hydroxylase (TH)-positive substantia nigra neurons from death induced by 5 x 30 mg/kg MPTP. However, the decrease of dopamine in the striatum was only partially prevented. In mice treated with pioglitazone, there were a reduced activation of microglia, reduced induction of iNOS-positive cells and less glial fibrillary acidic protein positive cells in both striatum and substantia nigra pars compacta. In addition, treatment with pioglitazone almost completely blocked staining of TH-positive neurons for nitrotyrosine, a marker of NO-mediated cell damage. Because an increase in inhibitory protein-kappa-Balpha (IkappaBalpha) expression and inhibition of translocation of the nuclear factor kappaB (NFkappaB) subunit p65 to the nucleus in dopaminergic neurons, glial cells and astrocytes correlated with the protective effects of pioglitazone, our results suggest that pioglitazone sequentially acts through PPARgamma activation, IkappaBalpha induction, block of NFkappaB activation, iNOS induction and NO-mediated toxicity. In conclusion, treatment with pioglitazone may offer a treatment opportunity in PD to slow the progression of disease that is mediated by inflammation.
Collapse
Affiliation(s)
- Thomas Dehmer
- Neurodegeneration Laboratory, Center of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | | | | | | | | |
Collapse
|
5
|
Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, Bürk K, Matson W, Dichgans J, Beal MF, Bogdanov MB. Oxidative stress in patients with Friedreich ataxia. Neurology 2000; 55:1719-21. [PMID: 11113228 DOI: 10.1212/wnl.55.11.1719] [Citation(s) in RCA: 231] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Increased generation of reactive oxygen species may underlie the pathophysiology of Friedreich ataxia (FRDA). The authors measured concentrations of 8-hydroxy-2'-deoxyguanosine (8OH2'dG), a marker of oxidative DNA damage, in urine and of dihydroxybenzoic acid (DHBA), a marker of hydroxyl radical attack, in plasma of 33 patients with FRDA. They found a 2.6-fold increase in normalized urinary 8OH2'dG but no change in plasma DHBA as compared with controls. Oral treatment with 5 mg/kg/day of the antioxidant idebenone for 8 weeks significantly decreased urinary 8OH2'dG concentrations, indicating that 8OH2'dG may be useful in monitoring therapeutic interventions in patients with FRDA.-1721
Collapse
Affiliation(s)
- J B Schulz
- Department of Neurology, University of Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Bierhaus A, Haslbeck K, Morcos M, Schiekofer S, Andrassy M, Chen J, Humpert PM, Möller W, Tritschler H, Dehmer T, Neundörfer B, Heuss D, Schwaninger M, Häring H, Schleicher E, Nawroth P. Increased CML Deposition, Rage Expression, And NF‐κB Activation In Diabetic Neuropathy. J Peripher Nerv Syst 2000. [DOI: 10.1046/j.1529-8027.2000.005003173.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- A Bierhaus
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - Km Haslbeck
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - M Morcos
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - S Schiekofer
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - M Andrassy
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - J Chen
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - PM Humpert
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - W Möller
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - H Tritschler
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - T Dehmer
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - B Neundörfer
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - D Heuss
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - M Schwaninger
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - H‐U Häring
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - E Schleicher
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| | - Pp Nawroth
- Sekt. Vaskuläre Medizin, Med. Klinik IV und Inst. für Neuropharm. Univ. Tübingen, 1 Med. Klinik I und Neurolog. Klinik, Univ. Heidelberg, 2 Neurol. Klinik Universität Erlangen‐Nürnberg, ASTA‐Medica GmbH Frankfurt 3
| |
Collapse
|
7
|
Abstract
MPTP produces clinical, biochemical, and neuropathologic changes reminiscent of those that occur in idiopathic Parkinson's disease (PD). In the present study we show that MPTP treatment led to activation of microglia in the substantia nigra pars compacta (SNpc), which was associated and colocalized with an increase in inducible nitric oxide synthase (iNOS) expression. In iNOS-deficient mice the increase of iNOS expression but not the activation of microglia was blocked. Dopaminergic SNpc neurons of iNOS-deficient mice were almost completely protected from MPTP toxicity in a chronic paradigm of MPTP toxicity. Because the MPTP-induced decrease in striatal concentrations of dopamine and its metabolites did not differ between iNOS-deficient mice and their wild-type littermates, this protection was not associated with a preservation of nigrostriatal terminals. Our results suggest that iNOS-derived nitric oxide produced in microglia plays an important role in the death of dopaminergic neurons but that other mechanisms contribute to the loss of dopaminergic terminals in MPTP neurotoxicity. We conclude that inhibition of iNOS may be a promising target for the treatment of PD.
Collapse
Affiliation(s)
- T Dehmer
- Department of Neurology, University of Tübingen, Germany
| | | | | | | | | |
Collapse
|
8
|
Werner D, Schleicher S, Enkel S, Dehmer T, Northoff H, Flehmig B. Transfusion-Induced Hepatitis C Virus Infection without Detectable Antivirus Antibodies in the Recipient. Transfus Med Hemother 1998. [DOI: 10.1159/000053452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
9
|
Abstract
Sera from patients with chronic hepatitis C were examined for the presence of GBV-C/HGV RNA by RT-PCR. The amplified products, derived from the 5' non-coding, NS3, and NS5a regions, were detected in 19 (19%) of the 100 HCV RNA-positive samples. Analysis of GBV-C/HGV prevalence rates revealed that dual infections are related to shared parenteral risk factors. Intravenous drug abuse and multiple transfusions were the factors clearly associated with a simultaneous HCV and GBV-C/HGV infection. Apart from this, patients with dual infections had a statistically significant lower mean age compared to those patients infected solely by HCV. Determination of HCV genotypes involved in GBV-C/HGV coinfection by RFLP analysis showed no correlation between the presence of GBV-C/HGV and a distinct HCV genotype. The study demonstrates that, based on the assessment of risk criteria, GBV-C/HGV is transmitted efficiently parenterally and is frequently linked to hepatitis C coinfection, regardless of HCV genotype.
Collapse
Affiliation(s)
- S Schleicher
- Department of Medical Virology and Epidemiology of Viral Diseases, University of Tübingen, Germany
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
Sera from patients with chronic hepatitis C were examined for the presence of GBV-C/HGV RNA by RT-PCR. The amplified products, derived from the 5' non-coding, NS3, and NS5a regions, were detected in 19 (19%) of the 100 HCV RNA-positive samples. Analysis of GBV-C/HGV prevalence rates revealed that dual infections are related to shared parenteral risk factors. Intravenous drug abuse and multiple transfusions were the factors clearly associated with a simultaneous HCV and GBV-C/HGV infection. Apart from this, patients with dual infections had a statistically significant lower mean age compared to those patients infected solely by HCV. Determination of HCV genotypes involved in GBV-C/HGV coinfection by RFLP analysis showed no correlation between the presence of GBV-C/HGV and a distinct HCV genotype. The study demonstrates that, based on the assessment of risk criteria, GBV-C/HGV is transmitted efficiently parenterally and is frequently linked to hepatitis C coinfection, regardless of HCV genotype.
Collapse
Affiliation(s)
- S Schleicher
- Department of Medical Virology and Epidemiology of Viral Diseases, University of Tübingen, Germany
| | | | | | | | | | | |
Collapse
|